A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

Recruiting · NCT05970237 · Observational (researchers observe without assigning treatment) · Lead sponsor: Boryung Pharmaceutical Co., Ltd

What this trial is about

The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension

Age range

19 Years and older

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not specified

Study type

Observational (researchers observe without assigning treatment)

Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
Those who voluntarily signed a written personal information agreement to participate in this clinical study.
Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.

Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
Those who are expected to need insulin prescription during the study period
Pregnant women, breast-feeding women

2 locations listed.